基于结合的橄电解质和环极素的宿主-客体抗菌剂
Pengke Liu1, Yuhui Chen2, Donghao Yao3
1South China University of Technology, School of Materials Science and Engineering, CHINA.
Angewandte Chemie (International ed. in English)
|May 19, 2025
概括
一种新的白醇衍生的抗微生物药物DY6显示出高疗效,但也显示出毒性. 将其与SβCD (DY6@SβCD) 结合,显著降低了细胞毒性,同时保持了对MRSA的强烈抗菌活性,并防止了耐药性的发展.
科学领域:
- 药用化学 医学化学
- 超分子化学 超分子化学
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 抗菌素耐药性 (AMR) 是一个日益严重的全球卫生危机,需要新的治疗策略.
- 来自白醇的合橄电解质 (COEs) 具有潜在的抗微生物特性,但经常面临细胞毒性挑战.
- 两性抗菌剂经常在有效性和宿主细胞毒性之间进行权衡.
研究的目的:
- 开发一种新型抗菌剂,具有改善的类似药物的特性和降低的细胞毒性.
- 研究一种超分子宿主-客体复合物的疗效,以提高抗菌性能.
- 评估由白醇衍生的COE复合物对抗耐药细菌和感染模型中的潜力.
主要方法:
- 合成和表征一种由白醇衍生的抗微生物结合的橄电解质 (COE),DY6.6.
- 使用硫乙烯β-环氧 (SβCD) 形成一个宿主-客人包容复合体 (DY6@SβCD).
- 对细胞毒性 (IC50) 的评估,对MRSA的抗菌活性 (MIC) 和耐药性发展研究. 使用了体外和体外感染模型.
主要成果:
- 与DY6 (IC50 = 9.4 μg mL-1) 相比,DY6@SβCD复合物显著降低了细胞毒性 (IC50 > 128 μg mL-1),同时保持了对MRSA的强烈活性 (MIC = 2 μg mL-1).
- 光谱和热量测量分析证实了稳定的宿主-客体复合体形成,将增强的生物相容性归因于尺寸相容性和静电相互作用.
- 在MRSA感染的伤口和角膜模型中,DY6@SβCD在降低细菌负载和炎症方面表现出比万科米辛更高的疗效,没有观察到抗药性发展.
结论:
- 使用环极素对COEs的高分子复合是一种可行的策略,可以减轻细胞毒性并增强抗微生物药物的有效性.
- DY6@SβCD复合体代表了对抗耐药细菌感染的有希望的治疗候选者,包括MRSA.
- 这种方法为克服两性抗微生物药物固有的局限性提供了一条途径,并应对抗微生物药物耐药性的挑战.
相关概念视频
00:57Antibiotic Selection
Overview
01:17Ion Exchange
Ion exchange chromatography separates charged molecules from a solution by reversibly exchanging them with mobile, or 'active', ions associated with the oppositely charged stationary phase. This method can be used to separate ions, soften and deionize water, and purify solutions. The polymers comprising the ion-exchange column are high-molecular-weight and chemically stable polymers, crosslinked to be porous and essentially insoluble. They are also functionalized with either acidic or basic...
01:23Antimicrobial Proteins
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...